New insight on how bacteria evolve drug resistance could lead to improved antibiotic therapies: Exploiting a strategy known as collateral sensitivity in bacteria could lead to the development of novel and sustainable treatments Science Daily
Melinta Therapeutics Announces US FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) | Small Molecules | News Channels PipelineReview.com
Melinta Therapeutics Announces US FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) | Small Molecules | News Channels PipelineReview.com
Melinta Therapeutics Announces US FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) | Small Molecules | News Channels PipelineReview.com